Science Explorer Back to mapMap
Discussion
Institution · MediciNova (United States)

Most cited papers from MediciNova (United States)

MediciNova (United States)

What are the most cited papers from MediciNova (United States)?

The most cited paper from MediciNova (United States) is "Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis" (Robert J. Fox et al., 2018), with 291 citations. Next come "Efficacy of a filter device in the prevention of embolic events during carotid angioplasty and stenting: An ex vivo analysis" (209) and "Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast" (207).

Showing 45 of 45 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#Paper
1 Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis Robert J. Fox et al. · New England Journal of Medicine Open access 29 Aug 2018 291
2 Efficacy of a filter device in the prevention of embolic events during carotid angioplasty and stenting: An ex vivo analysis Takao Ohki, Gary S. Roubin, Frank J. Veith et al. · Journal of Vascular Surgery Open access Dec 1999 209
3 Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilast Yoonsang Cho, G.V. Crichlow, Jon J. Vermeire et al. · Proceedings of the National Academy of Sciences Open access 8 Jun 2010 207
4 Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression Tyler Joseph Alban, Defne Bayık, Balint Otvos et al. · Frontiers in Immunology Open access 18 Jun 2020 162
5 Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence Richard L. Bell, Marcelo F. Lopez, Changhai Cui et al. · Addiction Biology Open access 11 Nov 2013 140
6 Codeine-induced hyperalgesia and allodynia: investigating the role of glial activation Jacinta Lee Johnson, Paul Edward Rolan, Michaela Johnson et al. · Translational Psychiatry Open access 11 Nov 2014 95
7 Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis Robert J. Fox et al. · Contemporary Clinical Trials Open access 11 Aug 2016 66
8 Activation of adult rat CNS endothelial cells by opioid-induced toll-like receptor 4 (TLR4) signaling induces proinflammatory, biochemical, morphological, and behavioral sequelae Peter M. Grace et al. · Neuroscience Open access 18 Sep 2014 66
9 Albuterol Administration Is Commonly Associated With Increases in Serum Lactate in Patients With Asthma Treated for Acute Exacerbation of Asthma Lawrence M. Lewis, Ian T. Ferguson, Stacey L. House et al. · CHEST Journal 15 Aug 2013 56
10 Ibudilast sensitizes glioblastoma to temozolomide by targeting Macrophage Migration Inhibitory Factor (MIF) Wendy Ha, Hatice Sevim‐Nalkiran, Ashraf Zaman et al. · Scientific Reports Open access 27 Feb 2019 54
11 Systemic Administration of Propentofylline, Ibudilast, and (+)-Naltrexone Each Reverses Mechanical Allodynia in a Novel Rat Model of Central Neuropathic Pain Amanda Ellis, Julie L. Wieseler, Jacob Favret et al. · Journal of Pain Open access 9 Jan 2014 52
12 MN-166 (ibudilast) in Amyotrophic Lateral Sclerosis in a Phase IIb/III Study: COMBAT-ALS Study Design Bjorn E. Oskarsson, Nicholas John Maragakis, Richard Stanley Bedlack et al. · Neurodegenerative Disease Management Open access 24 Nov 2021 44
13 Antimicrobial Activity of Dequalinium Chloride against Leading Germs of Vaginal Infections Vera Della Casa, Harald Noll, Susanne Gonser et al. · Arzneimittelforschung 26 Dec 2011 40
14 Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial Suma Babu et al. · NeuroImage Clinical Open access 2021 38
15 Acute Neuroimmune Modulation Attenuates the Development of Anxiety-Like Freezing Behavior in an Animal Model of Traumatic Brain Injury Krista M. Rodgers, Florencia M. Bercum, Danielle L. McCallum et al. · Journal of Neurotrauma Open access 22 Mar 2012 36
16 Local Treatment of Vaginal Infections of Varying Etiology with Dequalinium Chloride or Povidone Iodine Eiko E. Petersen, Ernst Rainer Weissenbacher, Peter Hengst et al. · Arzneimittelforschung 26 Dec 2011 36
17 A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors Alejandro Daniel Ricart, Edward A. Ashton, Matthew M. Cooney et al. · Cancer Chemotherapy and Pharmacology 8 Feb 2011 34
18 Reversal of Established Traumatic Brain Injury-Induced, Anxiety-Like Behavior in Rats after Delayed, Post-Injury Neuroimmune Suppression Krista M. Rodgers, Yuetiva K. Deming, Florencia M. Bercum et al. · Journal of Neurotrauma Open access 16 Sep 2013 33
19 Supradural inflammatory soup in awake and freely moving rats induces facial allodynia that is blocked by putative immune modulators Julie L. Wieseler, Amanda Ellis, Andrew McFadden et al. · Brain Research Open access 16 Mar 2017 23
20 A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors Anne M. Traynor, Michael S. Gordon, Dona B. Alberti et al. · Investigational New Drugs Open access 12 May 2009 16
21 Evaluation of Bedoradrine Sulfate (MN-221), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist for the Treatment of Asthma via Intravenous Infusion Kazuko Matsuda, Malath M. Makhay, Kirk W. Johnson et al. · Journal of Asthma 25 Oct 2012 8
22 MN‐001, a novel oral anti‐inflammatory agent, suppresses bladder hyperactivity in a rat model Mahadevan Raj Rajasekaran, Kenneth W. Locke, C. Lowell Parsons · British Journal of Urology 4 Jul 2006 8
23 Adaptive Design Single Center Phosphodiesterase Type 4 ( PDE4 ) Inhibitor – Ibudilast ( MN-166-ALS-1201 ) Phase 1b / 2a Clinical Trial Double - Blind ( DB ) with Open Label Extension (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis ( ALS ) Patients [ 1 ] Not Requiring Non-Invasive Ventilation ( no NIV ) up to 5 years ( Early Cohort – EC ) and [ 2 ] Requiring Non-Invasive Ventilation ( NIV ) Benjamin Rix Brooks et al. · Neurology 18 Apr 2017 6
24 Repeated dyspnea score and percent FEV1 are modest predictors of hospitalization/relapse in patients with acute asthma exacerbation John E. Schneider, Lawrence M. Lewis, Ian T. Ferguson et al. · Respiratory Medicine Open access 8 Jul 2014 6
25 Efficacy of a new intravenous β2-adrenergic agonist (bedoradrine, MN-221) for patients with an acute exacerbation of asthma Stacey L. House, Kazuko Matsuda, Geoffrey O'Brien et al. · Respiratory Medicine Open access 14 Aug 2015 5
26 Enhancement of ABCA1 and ABCG1 Expression and Cholesterol Efflux by a Metabolite of Tipelukast: A Potential Therapeutic Strategy for Atherosclerosis Hongyan Qi, Masatsune Ogura, Kazuko Matsuda et al. · Journal of Atherosclerosis and Thrombosis Open access 21 Aug 2025 4
27 Effect of Ibudilast on Neurofilament-light Chain in Progressive MS: Analysis from a Phase II Trial (P3.2-033) Robert J. Fox, Matthew Karafa, Victoria König et al. · Neurology 9 Apr 2019 4
28 A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B) Benjamin D. Brooks et al. · Neurology 6 Apr 2015 3
29 Ibudilast - Phosphodiesterase Type 4 Inhibitor - Bi-Modal Therapy with Riluzole in Early [ Not Requiring Non-Invasive Ventilation ( NIV ) ] Cohort ( EC ) and Advanced [Requiring NIV ] ( ANC ) Amyotrophic Lateral Sclerosis ( ALS ) Patients - Single-Center Adaptive Design Six-Month Double-Blind ( DB ) - Placebo-Controlled Phase 1b/2a Epoch Followed by Six-Month Open Label Extension ( OLE ) Epoch, Wa Benjamin Brooks et al. · Neurology 10 Apr 2018 3
30 Evaluation of MN-221 (Bedoradrine), a Novel, Highly Selective Beta2-Adrenergic Receptor Agonist in Mild to Moderate Asthma via Intravenous Infusion Kazuko Matsuda, Yuichi Iwaki, Maria Feldman et al. · CHEST Journal Oct 2010 3
31 Adaptive Design Single Center Phosphodiesterase Type 4 (PDE4) Inhibitor - Ibudilast (MN-166-ALS-1201) Phase 1b/2a Clinical Trial Double-Blind (DB) with Open Label Extensions (OLE) [ NCT02238626 ] for Amyotrophic Lateral Sclerosis (ALS) Patients [1] Not Requiring Non-Invasive Ventilation (no-NIV) up to 5 Years (Early Cohort-EC) and [2] Requiring Non-Invasive Ventilation (NIV) up to 10 Years(Advance Benjamin Rix Brooks, Elena K. Bravver, Mohammed Sanjak et al. · Neurology 5 Apr 2016 2
32 A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (S50.005) Benjamin Rix Brooks et al. · Neurology 6 Apr 2015 1
33 Phase I study of MN-001, an oral anti-inflammatory agent for the treatment of asthma K W Locke · Journal of Allergy and Clinical Immunology Feb 2005 1
34 Are Temporal Graph Based Intrusion Detection Results Trustworthy? A Dataset Audit and Evaluation Framework Yinning Zhang, Sait Suer, s m tanvir faysal alam Chowdhoury et al. Conference paper Aug 2026 0
35 Multiverse Path Encryption for Securing Interpretation under Adversarial Access Shaoyuan Wu, Yinning Zhang Conference paper Aug 2026 0
36 Edible: An Integrated Smart-Fridge and Food-Management Ecosystem Djefafla Hachem, Hossem Eddine Hafidi, Telli Hatem et al. Conference paper Jul 2026 0
37 Biostimulants for sustainable agriculture: Challenges, validation needs and perspectives for field application Maria Grazia Tommasini, Sara Turci, Océane Edely et al. · Open Access Government Open access 14 Jul 2026 0
38 Additional file 1 of Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study David L. Wyles, Kazuko Matsuda, Yuichi Iwaki et al. · Figshare Open access 2 Apr 2026 0
39 Effect of MN-166 (ibudilast) on acute respiratory failure prevention in hospitalized participants with COVID-19: a randomized, double-blind, placebo-controlled phase 2 study David L. Wyles, Kazuko Matsuda, Yuichi Iwaki et al. · BMC Pulmonary Medicine Open access 2 Apr 2026 0
40 MN-002, The metabolite of MN-001 (tipelukast) promotes macrophage cholesterol efflux Qi Huicheng, Ogura Masatsune Ogura, Matsuda Kazuko et al. · Atherosclerosis Open access Aug 2024 0
41 Response to Treatment According to Progressive Disease Type: Analysis from a Phase II Progressive MS Trial of Ibudilast (S12.007) Andrew D. Goodman, Janel K. Barnes, Jon W. Yankey et al. · Neurology 9 Apr 2019 0
42 CTIM-36. IMMUNOHISTOCHEMISTRY EVALUATION ON PRE-TREATMENT TUMOR TISSUE PREDICTS TREATMENT RESPONSE TO MN-166 (IBUDILAST) AND TEMOZOLOMIDE COMBINATION THERAPY IN GLIOBLASTOMA PATIENTS Justin Durla Lathia, Adam J. Lauko, Kazuko Matsuda et al. · Neuro-Oncology Open access Nov 2023 0
43 Response Lawrence M. Lewis, Ian T. Ferguson, Stacey L. House et al. · CHEST Journal Open access Jun 2014 0
44 A Mobile Sensor System to Detect Water Hold-Up Locations and Internal Corrosion in Pipelines Narasi Sridhar, Garth W. Tormoen, Ashok Sabata et al. · Volume 2: Integrity Management; Poster Session; Student Paper Competition Conference paper 2006 0
45 Effects Of MN-001 In Patients With Mild-to-moderate Asthma In A Randomized, Double-blind And Placebo-controlled Phase II Study William W. Busse, Harold S. Nelson, P.E. Korenblat et al. · Journal of Allergy and Clinical Immunology Open access 2007 0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.